Description
Adalimumab is a tumor necrosis factor (TNF) blocker used for Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Ulcerative Colitis (UC), Crohn’s Disease (CD), Plaque Psoriasis (Ps), Hidradenitis Suppurativa (HS), and Uveitis (UV).
Dosage and Side Effects
Dosage of Adalimumab should be administered by subcutaneous injection.
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis:
- Recommended Dosage for adults is 40 mg every other week. Some patients with Rheumatoid Arthritis not taking methotrexate may benefit from enhancing the dosage to 40mg every week or 80mg every other week.
Juvenile Idiopathic Arthritis or Pediatric Uveitis:
- Recommended Dosage for Pediatric Weight (2 Years of Age and Older) 10 kg (22 lbs) to less than 15 kg (33 lbs), 15 kg (33 lbs) to less than 30 kg (66 lbs), 30 kg (66 lbs) and greater is 10 mg, 20 mg, 30 mg every other week respectively.
Crohn’s Disease:
- Recommended Dosage for Adults is 160 mg on Day 1 (given in 1-day or split over 2-consecutive days); 80 mg on Day 15; and 40mg every other week starting on Day 29.
- Recommended Dosage for Pediatric Patients Weight (6 Years of Age and Older) 17 kg (37 lbs) to less than 40 kg (88 lbs): 80 mg on Day 1; 40 mg on Day 15; and 20mg every other week starting on Day 29.
- Recommended Dosage for Pediatric Patients Weight 40 kg (88 lbs) and greater; 160 mg on Day 1 (single dose or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29.
Ulcerative Colitis:
- Recommended Dosage for Adults: 160 mg on Day 1 (given in 1-day or split over 2-consecutive days), 80 mg on Day 15, and 40 mg every other week starting on Day 29. Discontinue in patients without outcomes of clinical remission by 8 weeks (Day 57).
- Recommended Dosage for Pediatric Patients (5 Years of Age and Older) Weight 20 kg (44 lbs) to less than 40 kg (88 lbs): 80 mg on Day 1; 40 mg on Day 8; 40 mg on Day 15; 40 mg every other week or 20 mg every week starting on Day 29.
- Recommended Dosage for Pediatric Patients (5 Years of Age and Older) Weight 40 kg (88 lbs) and greater: 160 mg on Day 1 (single dose or split over two consecutive days); 80 mg on Day 8; 80 mg on Day 15; and 80 mg every other week or 40 mg every week starting on Day 29.
Continue the recommended pediatric dosage in patients who turn 18 years of age and who are well-controlled on their Adalimumab regimen.
Plaque Psoriasis or Adult Uveitis:
- Recommended Dosage for Adults: 80 mg initial dose, followed by 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa:
- Recommended Dosage for Adults: 160 mg on Day 1 (given in one day or split over two consecutive days); 80 mg on Day 15; 80 mg on Day 29 and subsequent doses: 40 mg every week or 80 mg every other week.
- Recommended Dosage for Adolescents (12 years of age and older) Weight 30 kg (66 lbs) to less than 60 kg (132 lbs): 80 mg on Day 1; For Day 8 and subsequent doses: 40 mg every other week.
- Recommended Dosage for Adolescents (12 years of age and older) Weight 60 kg (132 lbs) and greater: 160 mg on Day 1 (given in 1 day or split over 2-consecutive days); 80 mg on Day 15; For Day 29 and subsequent doses: 40mg every week or 80mg every other week.
The most commonly reported side effects due to adalimumab injection include infections (e.g. upper respiratory, sinusitis), headache, injection site reactions, and rash.
FAQ's
What type of drug is Adalimumab?
Adalimumab (Exemptia) specifically is a type of drug known as tumor necrosis factor (TNF) inhibitors.
Is Exemptia 40 mg a bio-similar medicinal product?
Yes, exemptia 40 mg is the first ADA biosimilar medicinal product.
Is Adalimumab a biologic?
Yes, Adalimumab is a kind of medication known as biological therapy.
Who should not take Exemptia?
You should not start taking Exemptia in case you have any kind of infection unless your health specialist says it is okay.